Preparing antiviral defenses Antiviral drugs are an important tool in the battle against COVID-19. Both remdesivir and molnupiravir, which target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase, were first developed against other RNA viruses. This highlights the importance of broad-spectrum antivirals that can be rapidly deployed against related emerging pathogens. Sourimant et al . used respiratory syncytial virus (RSV) as a primary indication in identifying further drugs that target the polymerase enzyme of RNA viruses. The authors explored derivatives of molnupiravir and identified 4′ fluorouridine (EIDD-2749) as an inhibitor of the polymerase of RSV and SARS-CoV-2. This drug can be delivered orally and was effective against RSV in mice and SARS-CoV-2 in ferrets. —VV

中文翻译：

---

4'-氟尿苷是一种口服抗病毒药，可阻断呼吸道合胞病毒和 SARS-CoV-2 复制

准备抗病毒防御 抗病毒药物是对抗 COVID-19 的重要工具。瑞德西韦和莫鲁匹拉韦均针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 聚合酶，最初是针对其他 RNA 病毒而开发的。这凸显了可以快速部署针对相关新兴病原体的广谱抗病毒药物的重要性。苏里芒等人。使用呼吸道合胞病毒（RSV）作为识别进一步针对 RNA 病毒聚合酶的药物的主要适应症。作者探索了 molnupiravir 的衍生物，并鉴定出 4' 氟尿苷 (EIDD-2749) 是 RSV 和 SARS-CoV-2 聚合酶的抑制剂。该药物可口服，可有效对抗小鼠 RSV 和雪貂 SARS-CoV-2。—VV